Evidence map›Paper›PMID 38281044›Full record

ArticleMalaria journal2024

msp1, msp2, and glurp genotyping to differentiate Plasmodium falciparum recrudescence from reinfections during prevention of reestablishment phase, Sri Lanka, 2014-2019.

Kumudunayana T Gunasekera, Risintha G Premaratne, Shiroma M Handunnetti, Jagathpriya Weerasena, Sunil Premawansa, Deepika S Fernando

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kumudunayana T GunasekeraAnti Malaria Campaign, Ministry of Health, 555/5 Public Health Complex, Elvitigala Mawatha, Colombo 5, Sri Lanka. kumudunayana@yahoo.com.
Risintha G PremaratneWorld Health Organization Regional Office for South-East Asia, New Delhi, India.
Shiroma M HandunnettiInstitute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo, Sri Lanka.
Jagathpriya WeerasenaInstitute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo, Sri Lanka.
Sunil PremawansaDepartment of Zoology and Environmental Science, University of Colombo, Colombo, Sri Lanka.
Deepika S FernandoDepartment of Parasitology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
University of Colombo · LKAnti Filariasis Campaign · LKWorld Health Organization Regional Office for South-East Asia · IN

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundSri Lanka after eliminating malaria in 2012, is in the prevention of re-establishment (POR) phase. Being a tropical country with high malariogenic potential, maintaining vigilance is important. All malaria cases are investigated epidemiologically and followed up by integrated drug efficacy surveillance (iDES). Occasionally, that alone is not adequate to differentiate Plasmodium falciparum reinfections from recrudescences. This study evaluated the World Health Organization and Medicines for Malaria Venture (MMV) recommended genotyping protocol for the merozoite surface proteins (msp1, msp2) and the glutamate-rich protein (glurp) to discriminate P. falciparum recrudescence from reinfection in POR phase.

methodsAll P. falciparum patients detected from April 2014 to December 2019 were included in this study. Patients were treated and followed up by iDES up to 28 days and were advised to get tested if they develop fever at any time over the following year. Basic socio-demographic information including history of travel was obtained. Details of the malariogenic potential and reactive entomological and parasitological surveillance carried out by the Anti Malaria Campaign to exclude the possibility of local transmission were also collected. The msp1, msp2, and glurp genotyping was performed for initial and any recurrent infections. Classification of recurrent infections as recrudescence or reinfection was done based on epidemiological findings and was compared with the genotyping outcome.

resultsAmong 106 P. falciparum patients, six had recurrent infections. All the initial infections were imported, with a history of travel to malaria endemic countries. In all instances, the reactive entomological and parasitological surveillance had no evidence for local transmission. Five recurrences occurred within 28 days of follow-up and were classified as recrudescence. They have not travelled to malaria endemic countries between the initial and recurrent infections. The other had a recurrent infection after 105 days. It was assumed a reinfection, as he had travelled to the same malaria endemic country in between the two malaria attacks. Genotyping confirmed the recrudescence and the reinfection.

conclusionsThe msp1, msp2 and glurp genotyping method accurately differentiated reinfections from recrudescence. Since reinfection without a history of travel to a malaria endemic country would mean local transmission, combining genotyping outcome with epidemiological findings will assist classifying malaria cases without any ambiguity.

Indexed as

Frontotemporal DementiaMalaria, FalciparumMerozoite Surface Protein 1Muscular Dystrophies, Limb-GirdleMyositis, Inclusion BodyOsteitis DeformansAntigens, ProtozoanGenetic VariationGenotypeGlutamic AcidHumansMalePlasmodium falciparumProtozoan ProteinsRecurrenceReinfectionAntigens, ProtozoanGlutamic AcidMerozoite Surface Protein 1Protozoan ProteinsGenotypingGlurpMalaria prevention of re-establishmentmsp1msp2Recrudescence

Identifiers

PMID38281044
PMCPMC10821543
OpenAlexW4391275082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.